AARON OSBORNE, M.D., PH.D.
Osteopathic Medicine at Oakfield Dr, Brandon, FL
License number
Florida ME108215
Category
Osteopathic Medicine
Type
Emergency Medicine
Address
Address
2
119 Oakfield Dr, Brandon, FL 33511
18232 Clear Lake Dr, Lutz, FL 33548
18232 Clear Lake Dr, Lutz, FL 33548
Phone
(813) 571-5150
(813) 482-5599
(813) 482-5599
Personal information
See more information about AARON OSBORNE at radaris.comName
Address
Phone
440 Arizona Ave, Fort Lauderdale, FL 33312
10814 N Teegreen Rd, Tampa, FL 33612
18232 Clear Lake Dr, Lutz, FL 33548
440 Arizona Ave, Fort Lauderdale, FL 33312
3620 3Rd St, Fort Lauderdale, FL 33311
Professional information
See more information about AARON OSBORNE at trustoria.com
Dr. Aaron Osborne, Clearwater FL - MD (Doctor of Medicine)
Dr. Aaron Osborne, Clearwater FL - MD (Doctor of Medicine)
Specialties:
Emergency Medicine
Address:
EMCARE -SE REGION
18167 Us Highway 19 N SUITE 650, Clearwater 33764
(727) 507-2505 (Phone), (727) 507-3630 (Fax)
Emcare
119 Oakfield Dr, Brandon 33511
(800) 507-8874 (Phone)
18167 Us Highway 19 N SUITE 650, Clearwater 33764
(727) 507-2505 (Phone), (727) 507-3630 (Fax)
Emcare
119 Oakfield Dr, Brandon 33511
(800) 507-8874 (Phone)
Languages:
English
Education:
Medical School
University of South Florida / College of Medicine
Graduated: 2007
University of South Florida / College of Medicine
Graduated: 2007
Aaron Osborne, Brandon FL
Aaron Osborne, Brandon FL
Specialties:
Emergency Medicine Physician
Address:
119 Oakfield Dr, Brandon, FL 33511
Assay For Transcriptionally Active Methylated Promoters
Assay For Transcriptionally Active Methylated Promoters
US Patent:
2007018, Aug 9, 2007
Filed:
Apr 16, 2007
Appl. No.:
11/735706
Inventors:
George Blanck - Tampa FL, US
Melissa Niesen - Tampa FL, US
Aaron Osborne - Lutz FL, US
Melissa Niesen - Tampa FL, US
Aaron Osborne - Lutz FL, US
Assignee:
UNIVERSITY OF SOUTH FLORIDA - Tampa FL
International Classification:
C12Q 1/68, C12Q 1/66
US Classification:
435006000, 435008000
Abstract:
A method of identifying genes that can be activated when methylated; as well as proteins that mediate such activation. The method allows identification of HLA-DRA silencing agents expected to be of therapeutic value in the treatment of inflammation associated with HLA-DRA expression.